

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet		1	of	1	Application Number 10/551,557
					Filing Date October 3, 2005
					First Named Inventor Christos TSAKLAKIDIS et al.
					Group Art Unit 1626
					Examiner Name Sun Jae Y Loewe
					Attorney Docket Number MERCK-2723

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Database Beilstein Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE August 9, 1996, XP002283422	
		Database Beilstein Beilstein Institute for Organic Chemistry, Frankfurt-Main, De; June 27, 1988 XP002282645.	
		Database Beilstein Beilstein Institute fro Organic Chemistry, Frankfurt-Main, DE June 27, 1988 XP002282646	
		Database Beilstein Beilstein Institute for Organic Chemistry, Frankfurt-Main, DE March 19, 1991, XP002282647.	
		Griesser, U.L., "The Importance of Solvates", Polymorphism: in the Pharmaceutical industry, Edited by Rolf Hilfiker, Copyright 2006 WILEY-VCH Verlag GmbH & Co. KgaA, Weinheim ISBN: 3-527-31146-7, pps. 211 – 233.	
		Vippagunta, S. R., et al., "Crystalline Solids", Advanced Drug Delivery Reviews, 48 (2001) 3-26.	

Examiner Signature	Date Considered	
-----------------------	--------------------	--

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.